Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

SelankvsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED11/40 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
Selank
Anxiolytic + Cognitive · Russian Pharma
150–300 mcg/doseIntranasalZaderej 2014
~30 minOnset
Intranasal · 2–3×/day during stress / cognitive demand
Testagen
Bioregulator Peptide · Khavinson School
Lys-Glu-Asp-GlySequenceFedoreyeva 2011
NuclearLocalizationFedoreyeva 2011
TesticularTissue target
SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter
Selank
Testagen
Primary target
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Testicular tissue; proposed nuclear DNA interaction
Pathway
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
No GABA-receptor binding; no dependence reportedMedvedev 2007
Unknown — no HPG axis data
Origin
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development

02Dosage Protocols

Parameter
Selank
Testagen
Standard dose
150–300 mcg / dose intranasalZaderej 2014
Frequency
2–3× per day during stress
Once daily or alternate days
Lower / starter dose
75 mcg / dose
Evidence basis
Human-mechanistic + Russian clinical trialsMedvedev 2007
Animal mechanistic / in vitro onlyFedoreyeva 2011
Duration
10–14 day cycles, repeated as needed
Reconstitution
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Sterile water or bacteriostatic saline
Timing
Morning + early afternoon preferred
Half-life
Short (minutes plasma); CNS effect lasts ~3 hr
Unknown — likely minutes (short peptide)
Typical protocol (anecdotal)
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
Subcutaneous

04Side Effects & Safety

Parameter
Selank
Testagen
Nasal irritation
Mild burning or congestion (transient)
Sedation
None — distinct from benzodiazepinesMedvedev 2007
Dependence / withdrawal
None reported in clinical useZaderej 2014
Cognitive impairment
None — opposite effect (enhancement)
Allergic reaction
Rare hypersensitivity
Long-term safety
Limited Western RCT data
Unknown — no long-term studies
Pregnancy / OB
Avoid — insufficient data
Injection site reactions
Erythema, mild irritation (potential)
Systemic effects
Unknown — no human safety data
Hormonal impact
No published data on testosterone, LH, FSH effects
Absolute Contraindications
Selank
  • ·Pregnancy / breastfeeding
  • ·Hypersensitivity to peptide
Testagen
  • ·Active testicular malignancy
Relative Contraindications
Selank
  • ·Active autoimmune disease (theoretical via immunomodulation)
Testagen
  • ·Hormone-sensitive cancers (no data; theoretical caution)
  • ·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter
Selank
Testagen
1. Form
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Administration
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage
Refrigerate after reconstitution; ≤30 days. Light-protected.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Caveat
Avoid co-administration with strong sedatives or other anxiolytics initially.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.